A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers
- Registration Number
- NCT00992342
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to investigate safety and toleration of multiple oral doses as well as the time course of PF-03893787 concentration in the blood following dosing by oral solution.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- Healthy male subjects and females of non-childbearing potential between the ages of 18 and 55 years.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 21 drinks/week for males and 14 drinks/week for females.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-03893787 5 mg PF-03893787 - PF-03893787 50 mg PF-03893787 - PF-03893787 15 mg PF-03893787 -
- Primary Outcome Measures
Name Time Method Safety/toleration: Adverse events, vital signs, 12 lead ECG, blood (including creatine kinase) and urine safety tests and physical examination. 22 days
- Secondary Outcome Measures
Name Time Method Pharmacokinetic parameters: Cmax, Tmax, AUCτ, t½, accumulation ratio, 22 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular targets and mechanisms of PF-03893787 in phase 1 trials?
How does PF-03893787 compare to other kinase inhibitors in early-phase healthy volunteer studies?
What biomarkers correlate with pharmacokinetic profiles of PF-03893787 in phase 1 research?
What adverse events were observed in NCT00992342 and how were they managed in healthy subjects?
Are there combination therapies or related compounds to PF-03893787 in Pfizer's early-stage pipeline?
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇧🇪Bruxelles, Belgium
Pfizer Investigational Site🇧🇪Bruxelles, Belgium